Market Place
Sourcing Support
Heron Therapeutics Announces Q3 2024 Financial Results & Guidance
12 Nov 2024 //
PR NEWSWIRE
Heron Reaffirms Supply Of Alternatives During IV Fluid Shortage
10 Oct 2024 //
PR NEWSWIRE
Heron Announces FDA Approval for Zynrelef
25 Sep 2024 //
PR NEWSWIRE
Heron Therapeutics Appoints Brett Fleshman as Chief Business Officer
03 Sep 2024 //
PR NEWSWIRE
Heron Therapeutics Taps Brett Fleshman as Chief Business Officer
03 Sep 2024 //
CONTRACT PHARMA
ZYNRELEF Included As Qualifying Product Under Proposed Non-Opioid Policy
15 Jul 2024 //
PR NEWSWIRE
Heron`s ZYNRELEF Vial Access Needle Application Accepted
02 Jul 2024 //
PR NEWSWIRE
Heron Submits PAS For ZYNRELEF Vial Access Needle To FDA
31 May 2024 //
PR NEWSWIRE
Heron Therapeutics Announces Partnership with CrossLink Life Sciences
07 Jan 2024 //
PR NEWSWIRE
Heron Therapeutics Announces Third Quarter 2023 Financial Results
14 Nov 2023 //
PR NEWSWIRE
Heron launches patent suit against Mylan over potential generic for nausea
19 Sep 2023 //
ENDPTS
Heron lays off 25% of staff in second round of cuts in 13 months
24 Jul 2023 //
FIERCE BIOTECH
Heron Therapeutics Announces Appointment of Ira Duarte as CFO
23 Jun 2023 //
PR NEWSWIRE
Heron Announces Appointment of William Forbes as Chief Development Officer
12 Jun 2023 //
PR NEWSWIRE
Heron Therapeutics Announces New CEO and Board Chairman
03 Apr 2023 //
PR NEWSWIRE
Heron Therapeutics Announces CMS Granted Pass-through Payment Status for APONVIE
13 Mar 2023 //
PR NEWSWIRE
Heron Announces Presentation at 43rd Annual Cowen Healthcare Conference
27 Feb 2023 //
PR NEWSWIRE
Heron Therapeutics Announces Filing of an Efficacy Supplement for ZYNRELEF
29 Dec 2022 //
PR NEWSWIRE
Heron scores FDA for Aponvie, alternative to pills for postoperative nausea
20 Sep 2022 //
FIERCEPHARMA
Heron Therapeutics Announces U.S. FDA Approval of APONVIE (HTX-019)
16 Sep 2022 //
PRNEWSWIRE
Enforcement Report - Week of August 24, 2022
24 Aug 2022 //
FDA
Heron Therapeutics Announces $76.5 Million Private Placement Financing
09 Aug 2022 //
PRESS RELEASE
Heron Announces Financial Results for the Three and Six Months
09 Aug 2022 //
PRESS RELEASE
Heron Therapeutics to Report Second Quarter 2022 Financial Results
02 Aug 2022 //
PRESS RELEASE
Heron Therapeutics Announces Restructuring and Cost Reduction Plan
01 Jul 2022 //
BIOSPACE
Heron Tx Shows ZYNRELEF as Perioperative Non-Opioid Multimodal Analgesic Regimen
14 Jun 2022 //
PRNEWSWIRE
Heron Therapeutics Presents ZYNRELEF Data at the SOAP
16 May 2022 //
PRNEWSWIRE
Heron Tx Announces Financial Results for the Three Months Ended March 31, 2022
09 May 2022 //
PRNEWSWIRE
Heron Tx says Approval of ZYNRELEF by Health Canada for Postoperative Pain
17 Mar 2022 //
PRNEWSWIRE
Heron Tx Announces Financial Results December 31, 2021
28 Feb 2022 //
PRNEWSWIRE
FDA approves expansion for ZYNRELEF
10 Dec 2021 //
PHARMAFILE
Heron Announces FDA Approval of Significant Indication Expansion for ZYNRELEF
09 Dec 2021 //
PRNEWSWIRE
Heron Submits HTX-019 NDA for Prevention of Postoperative Nausea and Vomiting
18 Nov 2021 //
PRNEWSWIRE
Heron Announces Results for Q1 & Q3 2021 & Highlights Corporate Updates
03 Nov 2021 //
HERONTX
Heron Results from HOPE Showing ZYNRELEF Need for Opioids With 95% of Patients
28 Jul 2021 //
PRNEWSWIRE
Heron Therapeutics Announces 340B Prime Vendor Contract with Apexus
07 Jul 2021 //
PR NEWSWIRE
Heron Therapeutics Announces 340B Prime Vendor Contract with Apexus
07 Jul 2021 //
PR NEWSWIRE
Heron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF
01 Jul 2021 //
PR NEWSWIRE
Heron Therapeutics Announces $150 Million Convertible Debt Financing
25 May 2021 //
PRNEWSWIRE
Heron`s Zynrelef could hit blockbuster heights, analysts predict
15 May 2021 //
FIERCE PHARMA
Third time’s the charm as Heron wins FDA nod for non-opioid anesthetic Zynrelef
15 May 2021 //
ENDPTS
Heron Announces Publication of Results from EPOCH 1 Follow-On Study of HTX-011
21 Jan 2021 //
PRNEWSWIRE
Heron Announces Publication of Results from EPOCH 1 Follow-On Study of HTX-011
21 Jan 2021 //
PRESS RELEASE
Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011
13 Nov 2020 //
PRNEWSWIRE
Heron Announces Financial Results for the Three and Nine Months Ended Sep 30
05 Nov 2020 //
PRNEWSWIRE
Heron Therapeutics’ Zynrelef receives European marketing approval
29 Sep 2020 //
PHARMABIZ
Heron Therapeutics to Present at Cantor Virtual Global Healthcare Conference
11 Sep 2020 //
PRNNEWSWIRE
Heron Announces Successful FDA Meeting for Postoperative Pain Treatment
09 Sep 2020 //
USA PHARMACEUTICALREVIEW
Heron Therapeutics Announces Outcome of FDA Type A Meeting to Discuss HTX-011
08 Sep 2020 //
PRESS RELEASE
Heron Therapeutics Announces Financial Results for the Three and Six Months
05 Aug 2020 //
PRNEWSWIRE
Heron Receives Positive CHMP Opinion for ZYNRELEF™ (HTX-011) for the Management
24 Jul 2020 //
PRNEWSWIRE
Novartis, Gilead, GSK grab positive CHMPs; Menarini and Radius sign up to $350M
24 Jul 2020 //
ENDPTS
Heron Therapeutics Announces Initiation of Phase 2 Clinical Study of CINVANTI®
16 Jul 2020 //
PRNEWSWIRE
Heron`s wings clipped again with another FDA rejection
29 Jun 2020 //
FIERCE BIOTECH
Heron Announces Publication of Results from Study 209 2b Study of HTX-011
04 Jun 2020 //
PRNEWSWIRE
Heron Therapeutics begins phase 1b/2 study of HTX-034
19 May 2020 //
PHARMABIZ
Health Canada Grants Priority Review Status for Heron Therapeutics
03 Dec 2019 //
PR NEWSWIRE
